Related Experiment Video
Updated: Aug 8, 2026
08:12
Transduction-Transplantation Mouse Model of Myeloproliferative Neoplasm
Published on: December 22, 2016
Thrombopoietin-responsive essential thrombocythaemia with myelofibrosis
1First Department of Internal Medicine, School of Medicine, University of Tokushima, Japan.
British Journal of Haematology
|May 1, 1997
Summary
Thrombopoietin (TPO) may drive myelofibrosis in essential thrombocythaemia (ET). Elevated TPO stimulated neoplastic cell growth and increased platelet-derived growth factor (PDGF) production, suggesting a key role for TPO in ET-related myelofibrosis.
Area of Science:
- Hematology
- Oncology
- Cell Biology
Background:
- Myelofibrosis pathogenesis is linked to cytokines from megakaryocytes.
- Essential thrombocythaemia (ET) is a myeloproliferative neoplasm characterized by increased platelet counts.
Related Concept Videos
01:28Role of Hematopoietic Growth Factors
Hematopoietic growth factors are molecules that regulate the differentiation rate of hematopoietic stem cells (HSCs). Erythropoietin (EPO), primarily produced by the kidneys, plays a crucial role in erythrocyte production. When oxygen levels in the blood are low, EPO is released into the bloodstream, reaching the bone marrow, where it stimulates HSCs to differentiate and mature into erythrocytes, which are vital for oxygen transport.
Thrombopoietin (TPO), mainly released by the liver,...
Thrombopoietin (TPO), mainly released by the liver,...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...